<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006681</url>
  </required_header>
  <id_info>
    <org_study_id>0560-09</org_study_id>
    <nct_id>NCT01006681</nct_id>
  </id_info>
  <brief_title>Vaccination Against Influenza H1N1 in Rheumatic Diseases</brief_title>
  <official_title>Efficacy and Safety of Vaccination Against Influenza H1N1 in Patients With Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriatic Arthritis and Ankylosing Spondylitis Treated With Immunomodulatory Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The spread of Influenza H1N1 has prompted the development of vaccines against this virus.
      Immunocompromised patients are at increased risk of developing complications of Influenza
      H1N1. The efficacy and safety of H1N1 vaccination have not been evaluated in this population
      of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients with Rheumatoid Arthritis (RA), 50 patients with Systemic Lupus Erythematosus
      (SLE), 50 patients with spondyloarthropathies (Psoriatic arthritis (PsA) and Ankylosing
      Spondylitis (AS) and 200 healthy subjects will participate in the study.

      All the subjects will be vaccinated with Focetria (Novartis) and will be evaluated the day of
      vaccination and 4 weeks later.

      The evaluation will include:

      Efficacy of the vaccine: Blood will be drawn on day 0 and 4 weeks later and tested for the
      presence of antibodies against A/California17/2009/H1N1 by hemagglutination inhibition test.

      Safety of the vaccine:

        -  Records of adverse event

        -  Assessment of disease activity : RA - Disease activity score (DAS 28), SLE - SLEDAI, PsA
           - DAS 28 and PASI, AS- BASDAI, ESR, CRP
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">April 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint : Proportion of patients who will achieve a titer of antibodies above 1/40 within the groups of patients in comparison with healthy subjects</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Endpoint: Safety of the vaccine with regard to disease activity by changes in DAS, SLEDAI and BASDAI</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Influenza</condition>
  <condition>Rheumatic Diseases</condition>
  <arm_group>
    <arm_group_label>Monovalent MF59-Adjuvanted vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Focetria (Monovalent MF59-Adjuvanted vaccine)</intervention_name>
    <description>7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate
Intra muscular</description>
    <arm_group_label>Monovalent MF59-Adjuvanted vaccine</arm_group_label>
    <other_name>Focetria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Focetria (Monovalent MF59-Adjuvanted vaccine)</intervention_name>
    <description>7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate
Intramuscular injection</description>
    <arm_group_label>Monovalent MF59-Adjuvanted vaccine</arm_group_label>
    <other_name>Focetria</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Focetria (Monovalent MF59-Adjuvanted vaccine)</intervention_name>
    <description>Monovalent MF59-Adjuvanted vaccine</description>
    <arm_group_label>Monovalent MF59-Adjuvanted vaccine</arm_group_label>
    <other_name>Focetria</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients suffering from: Rheumatoid Arthritis, Systemic Lupus Erythematosus,
             Ankylosing Spondylitis, Psoriatic Arthritis

          -  Able to firm an informed consent

          -  Aged - 18-65

          -  Candidates to receive vaccination against H1N1, according to the recommendation of the
             Ministry of Health

        Exclusion Criteria:

          -  Allergy to eggs

          -  Known allergy to seasonal influenza vaccine

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>November 2, 2009</last_update_submitted>
  <last_update_submitted_qc>November 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ori Elkayam</name_title>
    <organization>Tel Aviv Sourasky Medical Center</organization>
  </responsible_party>
  <keyword>rheumatoid</keyword>
  <keyword>SLE</keyword>
  <keyword>Psoriatic arthritis</keyword>
  <keyword>Ankylosing</keyword>
  <keyword>Influenza H1N1</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Vaccination against H1N1 in rheumatic diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>MF59 oil emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

